

# Wai Tong Ng

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/811672/publications.pdf>

Version: 2024-02-01

151  
papers

8,077  
citations

61984

43  
h-index

51608

86  
g-index

155  
all docs

155  
docs citations

155  
times ranked

6483  
citing authors

#	ARTICLE	IF	CITATIONS
1	Chemotherapy and radiotherapy in nasopharyngeal carcinoma: an update of the MAC-NPC meta-analysis. <i>Lancet Oncology</i> , 2015, 16, 645-655.	10.7	593
2	Management of Nasopharyngeal Carcinoma: Current Practice and Future Perspective. <i>Journal of Clinical Oncology</i> , 2015, 33, 3356-3364.	1.6	579
3	Evolution of treatment for nasopharyngeal cancer – Success and setback in the intensity-modulated radiotherapy era. <i>Radiotherapy and Oncology</i> , 2014, 110, 377-384.	0.6	300
4	Randomized Trial of Radiotherapy Plus Concurrent-Adjuvant Chemotherapy vs Radiotherapy Alone for Regionally Advanced Nasopharyngeal Carcinoma. <i>Journal of the National Cancer Institute</i> , 2010, 102, 1188-1198.	6.3	298
5	Current Management of Nasopharyngeal Cancer. <i>Seminars in Radiation Oncology</i> , 2012, 22, 233-244.	2.2	274
6	What Is the Best Treatment of Locally Advanced Nasopharyngeal Carcinoma? An Individual Patient Data Network Meta-Analysis. <i>Journal of Clinical Oncology</i> , 2017, 35, 498-505.	1.6	263
7	Proposal for the 8th edition of the AJCC/UICC staging system for nasopharyngeal cancer in the era of intensity-modulated radiotherapy. <i>Cancer</i> , 2016, 122, 546-558.	4.1	254
8	Clinical Outcomes and Patterns of Failure After Intensity-Modulated Radiotherapy for Nasopharyngeal Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 79, 420-428.	0.8	236
9	COVID-19 pandemic: Effects and evidence-based recommendations for otolaryngology and head and neck surgery practice. <i>Head and Neck</i> , 2020, 42, 1259-1267.	2.0	218
10	International guideline for the delineation of the clinical target volumes (CTV) for nasopharyngeal carcinoma. <i>Radiotherapy and Oncology</i> , 2018, 126, 25-36.	0.6	214
11	Factors contributing to the efficacy of concurrent adjuvant chemotherapy for locoregionally advanced nasopharyngeal carcinoma: Combined analyses of NPC-9901 and NPC-9902 Trials. <i>European Journal of Cancer</i> , 2011, 47, 656-666.	2.8	196
12	The battle against nasopharyngeal cancer. <i>Radiotherapy and Oncology</i> , 2012, 104, 272-278.	0.6	191
13	Treatment outcomes of nasopharyngeal carcinoma in modern era after intensity modulated radiotherapy (IMRT) in Hong Kong: A report of 3328 patients (HKNPCSG 1301 study). <i>Oral Oncology</i> , 2018, 77, 16-21.	1.5	189
14	Management of locally recurrent nasopharyngeal carcinoma. <i>Cancer Treatment Reviews</i> , 2019, 79, 101890.	7.7	186
15	Phase II study of sunitinib as second-line treatment for advanced gastric cancer. <i>Investigational New Drugs</i> , 2011, 29, 1449-1458.	2.6	179
16	Preliminary results of trial NPC0501 evaluating the therapeutic gain by changing from concurrent adjuvant to induction concurrent chemoradiotherapy, changing from fluorouracil to capecitabine, and changing from conventional to accelerated radiotherapy fractionation in patients with locoregionally advanced nasopharyngeal carcinoma. <i>Cancer</i> , 2015, 121, 1328-1338.	4.1	152
17	Analysis of Plasma Epstein-Barr Virus DNA in Nasopharyngeal Cancer After Chemoradiation to Identify High-Risk Patients for Adjuvant Chemotherapy: A Randomized Controlled Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 3091-3100.	1.6	147
18	Whole-exome sequencing identifies multiple loss-of-function mutations of NF- $\kappa$ B pathway regulators in nasopharyngeal carcinoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 11283-11288.	7.1	144

#	ARTICLE	IF	CITATIONS
19	Comparison of Planning Quality and Efficiency Between Conventional and Knowledge-based Algorithms in Nasopharyngeal Cancer Patients Using Intensity Modulated Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2016, 95, 981-990.	0.8	126
20	Prognostic nomogram for refining the prognostication of the proposed 8th edition of the AJCC/UICC staging system for nasopharyngeal cancer in the era of intensity-modulated radiotherapy. Cancer, 2016, 122, 3307-3315.	4.1	125
21	The strength/weakness of the AJCC/UICC staging system (7th edition) for nasopharyngeal cancer and suggestions for future improvement. Oral Oncology, 2012, 48, 1007-1013.	1.5	109
22	A randomized trial on addition of concurrent-adjuvant chemotherapy and/or accelerated fractionation for locally-advanced nasopharyngeal carcinoma. Radiotherapy and Oncology, 2011, 98, 15-22.	0.6	102
23	Sensorineural Hearing Loss After Treatment of Nasopharyngeal Carcinoma: A Longitudinal Analysis. International Journal of Radiation Oncology Biology Physics, 2009, 73, 1335-1342.	0.8	98
24	International Guideline on Dose Prioritization and Acceptance Criteria in Radiation Therapy Planning for Nasopharyngeal Carcinoma. International Journal of Radiation Oncology Biology Physics, 2019, 105, 567-580.	0.8	96
25	Major Late Toxicities After Conformal Radiotherapy for Nasopharyngeal Carcinoma—Patient- and Treatment-Related Risk Factors. International Journal of Radiation Oncology Biology Physics, 2009, 73, 1121-1128.	0.8	95
26	Potential improvement of tumor control probability by induction chemotherapy for advanced nasopharyngeal carcinoma. Radiotherapy and Oncology, 2008, 87, 204-210.	0.6	90
27	Clinical recommendations for defining platinum unsuitable head and neck cancer patient populations on chemoradiotherapy: A literature review. Oral Oncology, 2016, 53, 10-16.	1.5	86
28	N-staging by magnetic resonance imaging for patients with nasopharyngeal carcinoma: Pattern of nodal involvement by radiological levels. Radiotherapy and Oncology, 2007, 82, 70-75.	0.6	84
29	The impact of dosimetric inadequacy on treatment outcome of nasopharyngeal carcinoma with IMRT. Oral Oncology, 2014, 50, 506-512.	1.5	83
30	Comparative methylome analysis in solid tumors reveals aberrant methylation at chromosome 6p in nasopharyngeal carcinoma. Cancer Medicine, 2015, 4, 1079-1090.	2.8	76
31	Epigenetic markers for noninvasive early detection of nasopharyngeal carcinoma by methylation-sensitive high resolution melting. International Journal of Cancer, 2015, 136, E127-35.	5.1	72
32	Whole-exome sequencing identifies <i>MST1R</i> as a genetic susceptibility gene in nasopharyngeal carcinoma. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 3317-3322.	7.1	71
33	A multicenter, phase 3, randomized trial of concurrent chemoradiotherapy plus adjuvant chemotherapy versus radiotherapy alone in patients with regionally advanced nasopharyngeal carcinoma: 10-year outcomes for efficacy and toxicity. Cancer, 2017, 123, 4147-4157.	4.1	70
34	Screening for family members of patients with nasopharyngeal carcinoma. International Journal of Cancer, 2005, 113, 998-1001.	5.1	67
35	Treatment of stage IV(A-B) nasopharyngeal carcinoma by induction-concurrent chemoradiotherapy and accelerated fractionation. International Journal of Radiation Oncology Biology Physics, 2005, 63, 1331-1338.	0.8	66
36	Therapeutic targeting of CBP/ $\beta$ -catenin signaling reduces cancer stem-like population and synergistically suppresses growth of EBV-positive nasopharyngeal carcinoma cells with cisplatin. Scientific Reports, 2015, 5, 9979.	3.3	59

#	ARTICLE	IF	CITATIONS
37	Reirradiation with intensity-modulated radiotherapy for locally recurrent T3 to T4 nasopharyngeal carcinoma. <i>Head and Neck</i> , 2017, 39, 533-540.	2.0	57
38	A novel Hsp90 inhibitor AT13387 induces senescence in EBV-positive nasopharyngeal carcinoma cells and suppresses tumor formation. <i>Molecular Cancer</i> , 2013, 12, 128.	19.2	54
39	Treatment of Stage IV(A-B) nasopharyngeal carcinoma by induction-concurrent chemoradiotherapy and accelerated fractionation: Impact of chemotherapy schemes. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 66, 1004-1010.	0.8	51
40	Nasopharyngeal carcinoma: Salvage of local recurrence. <i>Oral Oncology</i> , 2012, 48, 768-774.	1.5	50
41	A systematic review and recommendations on the use of plasma EBV DNA for nasopharyngeal carcinoma. <i>European Journal of Cancer</i> , 2021, 153, 109-122.	2.8	48
42	Role of MIF/CXCL8/CXCR2 signaling in the growth of nasopharyngeal carcinoma tumor spheres. <i>Cancer Letters</i> , 2013, 335, 81-92.	7.2	47
43	Staging of nasopharyngeal carcinoma – The past, the present and the future. <i>Oral Oncology</i> , 2014, 50, 549-554.	1.5	47
44	Characterization of PD-L1 expression and immune cell infiltration in nasopharyngeal cancer. <i>Oral Oncology</i> , 2017, 67, 52-60.	1.5	46
45	Induction chemotherapy with cisplatin and gemcitabine followed by accelerated radiotherapy and concurrent cisplatin in patients with stage IV(A-B) nasopharyngeal carcinoma. <i>Head and Neck</i> , 2006, 28, 880-887.	2.0	45
46	Clinical utility of plasma Epstein-Barr virus DNA and <i>ERCC1</i> single nucleotide polymorphism in nasopharyngeal carcinoma. <i>Cancer</i> , 2015, 121, 2720-2729.	4.1	43
47	International Recommendations on Reirradiation by Intensity Modulated Radiation Therapy for Locally Recurrent Nasopharyngeal Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 110, 682-695.	0.8	42
48	Chemotherapy for Nasopharyngeal Carcinoma – Current Recommendation and Controversies. <i>Hematology/Oncology Clinics of North America</i> , 2015, 29, 1107-1122.	2.2	39
49	Radical radiotherapy for nasopharyngeal carcinoma in elderly patients: The importance of co-morbidity assessment. <i>Oral Oncology</i> , 2012, 48, 162-167.	1.5	38
50	Quality of life in head and neck cancer survivors at 1 year after treatment: the mediating role of unmet supportive care needs. <i>Supportive Care in Cancer</i> , 2014, 22, 2917-2926.	2.2	38
51	The prognostic value of histological typing in nasopharyngeal carcinoma. <i>Oral Oncology</i> , 2012, 48, 429-433.	1.5	37
52	Surrogate End Points for Overall Survival in Loco-Regionally Advanced Nasopharyngeal Carcinoma: An Individual Patient Data Meta-analysis. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	6.3	37
53	NPC0501 trial on the value of changing chemoradiotherapy sequence, replacing 5-fluorouracil with capecitabine, and altering fractionation for patients with advanced nasopharyngeal carcinoma. <i>Cancer</i> , 2020, 126, 3674-3688.	4.1	37
54	Outcomes of nasopharyngeal carcinoma screening for high risk family members in Hong Kong. <i>Familial Cancer</i> , 2010, 9, 221-228.	1.9	36

#	ARTICLE	IF	CITATIONS
55	Phase II trial of capecitabine plus cisplatin as first-line therapy in patients with metastatic nasopharyngeal cancer. <i>Head and Neck</i> , 2012, 34, 1225-1230.	2.0	36
56	Parapharyngeal Extension of Nasopharyngeal Carcinoma: Still a Significant Factor in Era of Modern Radiotherapy?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 72, 1082-1089.	0.8	34
57	Familial nasopharyngeal carcinoma in Hong Kong: epidemiology and implication in screening. <i>Familial Cancer</i> , 2009, 8, 103-108.	1.9	34
58	Treatment of primary liver cancer using highly-conformal radiotherapy with kv-image guidance and respiratory control. <i>Radiotherapy and Oncology</i> , 2012, 102, 56-61.	0.6	34
59	Predictive factors and radiological features of radiation-induced cranial nerve palsy in patients with nasopharyngeal carcinoma following radical radiotherapy. <i>Oral Oncology</i> , 2013, 49, 49-54.	1.5	34
60	Prospective, Multicenter, Phase 2 Trial of Induction Chemotherapy Followed by Bio-Chemoradiotherapy for Locally Advanced Recurrent Nasopharyngeal Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 100, 630-638.	0.8	34
61	Metastasis-suppressing <i>NID2</i> , an epigenetically-silenced gene, in the pathogenesis of nasopharyngeal carcinoma and esophageal squamous cell carcinoma. <i>Oncotarget</i> , 2016, 7, 78859-78871.	1.8	33
62	Active surveillance of carbapenem-resistant Enterobacteriaceae in intensive care units: Is it cost-effective in a nonendemic region?. <i>American Journal of Infection Control</i> , 2016, 44, 394-399.	2.3	31
63	A Mixed-Methods Study of Unmet Supportive Care Needs Among Head and Neck Cancer Survivors. <i>Cancer Nursing</i> , 2019, 42, 67-78.	1.5	31
64	Should all nasopharyngeal carcinoma with masticator space involvement be staged as T4?. <i>Oral Oncology</i> , 2014, 50, 1188-1195.	1.5	30
65	NF- $\kappa$ B p65 Subunit Is Modulated by Latent Transforming Growth Factor- $\beta$ 2 Binding Protein 2 (LTBP2) in Nasopharyngeal Carcinoma HONE1 and HK1 Cells. <i>PLoS ONE</i> , 2015, 10, e0127239.	2.5	29
66	Challenges for Quality Assurance of Target Volume Delineation in Clinical Trials. <i>Frontiers in Oncology</i> , 2017, 7, 221.	2.8	28
67	Patterns of care and treatment outcomes for local recurrence of NPC after definite IMRT—A study by the HKNPCSC. <i>Head and Neck</i> , 2019, 41, 3661-3669.	2.0	28
68	Current management of stage IV nasopharyngeal carcinoma without distant metastasis. <i>Cancer Treatment Reviews</i> , 2020, 85, 101995.	7.7	28
69	Multigene pathway-based analyses identify nasopharyngeal carcinoma risk associations for cumulative adverse effects of <i>TERT</i> and <i>CLPTM1L</i> and DNA double-strand breaks repair. <i>International Journal of Cancer</i> , 2014, 135, 1634-1645.	5.1	26
70	Automatic segmentation for adaptive planning in nasopharyngeal carcinoma IMRT: Time, geometrical, and dosimetric analysis. <i>Medical Dosimetry</i> , 2020, 45, 60-65.	0.9	26
71	Prognostic Factors for Overall Survival in Nasopharyngeal Cancer and Implication for TNM Staging by UICC: A Systematic Review of the Literature. <i>Frontiers in Oncology</i> , 2021, 11, 703995.	2.8	25
72	Cost-analysis of XELOX and FOLFOX4 for treatment of colorectal cancer to assist decision-making on reimbursement. <i>BMC Cancer</i> , 2011, 11, 288.	2.6	24

#	ARTICLE	IF	CITATIONS
73	Concurrent-Adjuvant Chemoradiation Therapy for Stage III-IVB Nasopharyngeal Carcinoma—Exploration for Achieving Optimal 10-Year Therapeutic Ratio. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 101, 1078-1086.	0.8	23
74	Metastatic Squamous Cell Carcinoma to the Cervical Lymph Nodes From an Unknown Primary Cancer: Management in the HPV Era. <i>Frontiers in Oncology</i> , 2020, 10, 593164.	2.8	23
75	A phase II study of pemetrexed combined with cisplatin in patients with recurrent or metastatic nasopharyngeal carcinoma. <i>Oral Oncology</i> , 2012, 48, 441-444.	1.5	21
76	Trends and Patterns of Breast Conservation Treatment in Hong Kong: 1994–2007. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 74, 98-103.	0.8	20
77	Can the Analysis of ERCC1 Expression Contribute to Individualized Therapy in Nasopharyngeal Carcinoma?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 79, 1414-1420.	0.8	20
78	Crucifera sulforaphane (SFN) inhibits the growth of nasopharyngeal carcinoma through DNA methyltransferase 1 (DNMT1)/Wnt inhibitory factor 1 (WIF1) axis. <i>Phytomedicine</i> , 2019, 63, 153058.	5.3	19
79	Adjuvant chemoradiation for resected gastric cancer: a 10-year experience. <i>Gastric Cancer</i> , 2011, 14, 63-71.	5.3	18
80	If concurrent—adjuvant chemoradiotherapy is beneficial for locoregionally advanced nasopharyngeal carcinoma, would changing the sequence to induction—concurrent achieve better outcome?. <i>Journal of Radiation Oncology</i> , 2012, 1, 107-115.	0.7	18
81	Meta-analysis of chemotherapy in nasopharynx carcinoma (MAC-NPC): An update on 26 trials and 7080 patients. <i>Clinical and Translational Radiation Oncology</i> , 2022, 32, 59-68.	1.7	18
82	Nasopharyngeal carcinoma MHC region deep sequencing identifies HLA and novel non-HLA TRIM31 and TRIM39 loci. <i>Communications Biology</i> , 2020, 3, 759.	4.4	17
83	Current Trends and Controversies in the Management of Warthin Tumor of the Parotid Gland. <i>Diagnostics</i> , 2021, 11, 1467.	2.6	17
84	Chemotherapy for Nasopharyngeal Cancer: Neoadjuvant, Concomitant, and/or Adjuvant. <i>Current Treatment Options in Oncology</i> , 2015, 16, 44.	3.0	16
85	Second primary cancer after intensity-modulated radiotherapy for nasopharyngeal carcinoma: A territory-wide study by HKNPCSC. <i>Oral Oncology</i> , 2020, 111, 105012.	1.5	16
86	Clinical utility of serial analysis of circulating tumour cells for detection of minimal residual disease of metastatic nasopharyngeal carcinoma. <i>British Journal of Cancer</i> , 2020, 123, 114-125.	6.4	14
87	Network-meta-analysis of chemotherapy in nasopharyngeal carcinoma (MAC-NPC): An update on 8,221 patients.. <i>Journal of Clinical Oncology</i> , 2020, 38, 6523-6523.	1.6	14
88	Is Selective Neck Irradiation Safe for Node-Negative Nasopharyngeal Carcinoma?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 85, 902-903.	0.8	13
89	MicroRNA profiling study reveals miR-150 in association with metastasis in nasopharyngeal carcinoma. <i>Scientific Reports</i> , 2017, 7, 12012.	3.3	13
90	A multicenter randomized controlled trial (RCT) of adjuvant chemotherapy (CT) in nasopharyngeal carcinoma (NPC) with residual plasma EBV DNA (EBV DNA) following primary radiotherapy (RT) or chemoradiation (CRT).. <i>Journal of Clinical Oncology</i> , 2017, 35, 6002-6002.	1.6	13

#	ARTICLE	IF	CITATIONS
91	An analysis of the efficacy of serial screening for familial nasopharyngeal carcinoma based on Markov chain models. <i>Familial Cancer</i> , 2011, 10, 133-139.	1.9	12
92	IKBB tumor suppressive role in nasopharyngeal carcinoma via NF- $\kappa$ B-mediated signalling. <i>International Journal of Cancer</i> , 2016, 138, 160-170.	5.1	12
93	Dose volume effects of re-irradiation for locally recurrent nasopharyngeal carcinoma. <i>Head and Neck</i> , 2020, 42, 180-187.	2.0	11
94	Prognostic and therapeutic evaluation of nasopharyngeal carcinoma by dynamic contrast-enhanced (DCE), diffusion-weighted (DW) magnetic resonance imaging (MRI) and magnetic resonance spectroscopy (MRS). <i>Magnetic Resonance Imaging</i> , 2021, 83, 50-56.	1.8	11
95	Head and neck cancer in Hong Kong. <i>Japanese Journal of Clinical Oncology</i> , 2018, 48, 13-21.	1.3	10
96	Translational research in nasopharyngeal carcinoma. <i>Oral Oncology</i> , 2014, 50, 345-352.	1.5	9
97	Leukocyte telomere length associates with nasopharyngeal carcinoma risk and survival in Hong Kong Chinese. <i>International Journal of Cancer</i> , 2018, 143, 2289-2298.	5.1	9
98	Milk Consumption Across Life Periods in Relation to Lower Risk of Nasopharyngeal Carcinoma: A Multicentre Case-Control Study. <i>Frontiers in Oncology</i> , 2019, 9, 253.	2.8	9
99	Radiotherapy in the management of glottic squamous cell carcinoma. <i>Head and Neck</i> , 2020, 42, 3558-3567.	2.0	9
100	Dietary fiber intake from fresh and preserved food and risk of nasopharyngeal carcinoma: observational evidence from a Chinese population. <i>Nutrition Journal</i> , 2021, 20, 14.	3.4	9
101	Application of Artificial Intelligence for Nasopharyngeal Carcinoma Management – A Systematic Review. <i>Cancer Management and Research</i> , 2022, Volume 14, 339-366.	1.9	9
102	Proton Therapy for Squamous Cell Carcinoma of the Head and Neck: Early Clinical Experience and Current Challenges. <i>Cancers</i> , 2022, 14, 2587.	3.7	9
103	Test-retest reliability of a computer-assisted self-administered questionnaire on early life exposure in a nasopharyngeal carcinoma case-control study. <i>Scientific Reports</i> , 2018, 8, 7052.	3.3	8
104	Solar Ultraviolet Radiation and Vitamin D Deficiency on Epstein-Barr Virus Reactivation: Observational and Genetic Evidence From a Nasopharyngeal Carcinoma-Endemic Population. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa426.	0.9	7
105	Prognostic Biomarkers for Survival in Nasopharyngeal Carcinoma: A Systematic Review of the Literature. <i>Cancers</i> , 2022, 14, 2122.	3.7	7
106	Perceived unmet supportive care needs and determinants of quality of life among head and neck cancer survivors: a research protocol. <i>Journal of Advanced Nursing</i> , 2013, 69, 2750-2758.	3.3	6
107	Potential pitfalls in incorporating plasma Epstein-Barr virus DNA in the management of nasopharyngeal carcinoma. <i>Head and Neck</i> , 2020, 42, 446-455.	2.0	6
108	Limitation of radiological T3 subclassification of rectal cancer due to paucity of mesorectal fat in Chinese patients. <i>Hong Kong Medical Journal</i> , 2014, 20, 366-70.	0.1	6



#	ARTICLE	IF	CITATIONS
109	Can Radiation Therapy Quality Assurance Improve Nasopharyngeal Cancer Outcomes in Low- and Middle-Income Countries: Reporting the First Phase of a Prospective International Atomic Energy Agency Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 111, 1227-1236.	0.8	5
110	Dosimetric comparison of intensity modulated radiotherapy and intensity modulated proton therapy in the treatment of recurrent nasopharyngeal carcinoma. <i>Medical Dosimetry</i> , 2022, 47, 14-19.	0.9	5
111	Meta-analysis of chemotherapy in nasopharyngeal carcinoma (MAC-NPC): An update on 4,798 patients.. <i>Journal of Clinical Oncology</i> , 2014, 32, 6022-6022.	1.6	5
112	Adjuvant S-1 chemotherapy after curative resection of gastric cancer in Chinese patients: assessment of treatment tolerability and associated risk factors. <i>Hong Kong Medical Journal</i> , 2017, 23, 54-62.	0.1	5
113	Management of Nasopharyngeal Carcinoma in Elderly Patients. <i>Frontiers in Oncology</i> , 2022, 12, 810690.	2.8	5
114	Contemporary management of the neck in nasopharyngeal carcinoma. <i>Head and Neck</i> , 2021, 43, 1949-1963.	2.0	4
115	External Validation of a Nomogram to Predict Survival and Benefit of Concurrent Chemoradiation for Stage II Nasopharyngeal Carcinoma. <i>Cancers</i> , 2021, 13, 4286.	3.7	4
116	The International Atomic Energy Agency global initiatives on nasopharyngeal cancer treatment. <i>Chinese Clinical Oncology</i> , 2016, 5, 27-27.	1.2	4
117	A novel nomogram to predict overall survival in head and neck cancer survivors with radiation-induced brain necrosis. <i>Radiotherapy and Oncology</i> , 2022, 168, 121-129.	0.6	4
118	Dose-volume predictors of post-radiation primary hypothyroidism in head and neck cancer: A systematic review. <i>Clinical and Translational Radiation Oncology</i> , 2022, 33, 83-92.	1.7	4
119	Exploratory Study of NPC-0501 Trial: Optimal Cisplatin Dose of Concurrent and Induction/Adjuvant Chemotherapy for Locoregionally Advanced Nasopharyngeal Carcinoma. <i>Clinical Cancer Research</i> , 2022, 28, 2679-2689.	7.0	4
120	Cost minimization analysis of capecitabine versus 5-fluorouracil-based treatment for gastric cancer patients in Hong Kong. <i>Journal of Medical Economics</i> , 2017, 20, 541-548.	2.1	3
121	Special section on intensity-modulated radiation therapy for head and neck cancer (IMRT). <i>Oral Oncology</i> , 2019, 88, 49-50.	1.5	3
122	Treatment Outcomes of Primary Pulmonary Lymphoepithelioma-like Carcinoma: a Series of 22 Patients and Treatment Strategy Review. <i>Hong Kong Journal of Radiology</i> , 2013, 16, 270-277.	0.1	3
123	International Consensus on Delineation of Target Volumes and Organs at Risk. , 2019, , 239-261.		2
124	Advances in Radiotherapy. , 2019, , 263-288.		2
125	Proton/heavy ion therapy in salvage of locally recurrent nasopharyngeal carcinoma. <i>Annals of Nasopharynx Cancer</i> , 2020, 4, 4-4.	0.3	2
126	Standardization for oncologic head and neck surgery. <i>European Archives of Oto-Rhino-Laryngology</i> , 2021, 278, 4663-4669.	1.6	2



#	ARTICLE	IF	CITATIONS
127	Dose-Response Reduction in Risk of Nasopharyngeal Carcinoma From Smoking Cessation: A Multicenter Case-Control Study in Hong Kong, China. <i>Frontiers in Oncology</i> , 2021, 11, 699241.	2.8	2
128	Maintenance Capecitabine in Recurrent or Metastatic Nasopharyngeal Carcinoma—“Magic Bullet or Pandora’s Box?”. <i>JAMA Oncology</i> , 2022, , .	7.1	2
129	The Janus Face in Defining the Optimal Radiation Dose for Nasopharyngeal Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 113, 114-116.	0.8	2
130	Salvage of Local Recurrence. , 2019, , 289-312.		1
131	Knowledge-based planning in nasopharyngeal carcinoma. <i>Annals of Nasopharynx Cancer</i> , 0, 4, 6-6.	0.3	1
132	Low vitamin D exposure and risk of nasopharyngeal carcinoma: Observational and genetic evidence from a multicenter case-control study. <i>Clinical Nutrition</i> , 2021, 40, 5180-5188.	5.0	1
133	Abstract 4773: Aberrant methylation at chromosome 6p as novel biomarkers for diagnosis and prognosis of nasopharyngeal carcinoma. , 2015, , .		1
134	Single-nucleotide polymorphism (SNP) of excision repair cross complementation group 1 (ERCC1) in nasopharynx cancer (NPC): A companion biomarker study to Hong Kong NPC Study Group 0502 trial. <i>Journal of Clinical Oncology</i> , 2014, 32, 6029-6029.	1.6	1
135	Identifying Patients With Low-Risk Locoregionally Advanced Nasopharyngeal Carcinoma by Plasma Epstein-Barr Virus DNA for Chemotherapy Deintensification: Quo Vadis?. <i>Journal of Clinical Oncology</i> , 2022, 40, 1135-1138.	1.6	1
136	Disadvantaged Subgroups Within the Global Head and Neck Cancer Population: How Can We Optimize Care?. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2022, 42, 501-510.	3.8	1
137	A Single-Arm Phase 2 Trial on Induction Chemotherapy Followed by Concurrent Chemoradiation in Nasopharyngeal Carcinoma Using a Reduced Cumulative Dose of Cisplatin. <i>Frontiers in Oncology</i> , 2022, 12, 842281.	2.8	1
138	Impact of adjuvant chemoradiation for adenocarcinoma of stomach after curative gastrectomy in Chinese: A 7-year audit. <i>Surgical Practice</i> , 2010, 14, 85-91.	0.2	0
139	Re-irradiation for recurrent NPC—is the treatment merited at all?. <i>Annals of Nasopharynx Cancer</i> , 0, 1, 1-1.	0.3	0
140	913MO Second primary cancer after intensity-modulated radiotherapy for nasopharyngeal carcinoma in Hong Kong (2001-2010): A territory-wide study by HKNPCSG. <i>Annals of Oncology</i> , 2020, 31, S659-S660.	1.2	0
141	Diagnosis and Staging of Nasopharyngeal Cancer. <i>Practical Guides in Radiation Oncology</i> , 2021, , 1-21.	0.1	0
142	Precision radiotherapy in nasopharyngeal carcinoma. <i>Annals of Nasopharynx Cancer</i> , 0, 5, 1-1.	0.3	0
143	Re-irradiation versus surgery for locally recurrent nasopharyngeal carcinoma. <i>Lancet Oncology</i> , The, 2021, 22, e217.	10.7	0
144	Nasopharynx. <i>Medical Radiology</i> , 2009, , 57-73.	0.1	0

#	ARTICLE	IF	CITATIONS
145	Abstract 4148: Adverse effects of TERT-CLPTM1L and double-strand breaks repair contribute to risk for nasopharyngeal carcinoma. , 2014, , .		0
146	Five-year Treatment Outcomes for Stage II to III Rectal Cancer in a Single Cancer Institution. Hong Kong Journal of Radiology, 2014, 17, 255-266.	0.1	0
147	Abstract 1734: Preclinical study of HSP-90 inhibitor drug, AUY922 showed good efficacy in treatment of nasopharyngeal cancer. , 2015, , .		0
148	Management of Nasopharyngeal Carcinoma. , 2016, , 445-473.		0
149	Treatment of persistent/recurrent nodal disease in nasopharyngeal cancer. Current Opinion in Otolaryngology and Head and Neck Surgery, 2021, 29, 86-92.	1.8	0
150	In Reply to Abbasi et al.. International Journal of Radiation Oncology Biology Physics, 2022, 112, 262-263.	0.8	0
151	Induction Chemotherapy Docetaxel, Cisplatin, 5-Fluorouracil Followed by Concurrent Chemoradiotherapy in Stage IVA Nasopharyngeal Carcinoma. Clinical Oncology and Research, 2020, , 1-8.	0.0	0